Solenis v. Axchem & SNF: GPAM Patent Suit Dismissed by Court
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Solenis Technologies, LP et al. v. Axchem USA, Inc. et al. |
| Case Number | 1:24-cv-01417 (N.D. Ga.) |
| Court | U.S. District Court for the Northern District of Georgia |
| Duration | Apr 2024 – Jan 2025 9 months |
| Outcome | Dismissed without Prejudice |
| Patents at Issue | |
| Accused Products | Axchem’s AXSTRENGTH® line, SNF’s GPAM offerings (e.g., BONDSTAR® Onsite GPAM) |
Case Overview
The Parties
⚖️ Plaintiffs
Subsidiaries of Solenis, a global leader in water treatment and process chemicals, holding key GPAM polymer technology patents.
🛡️ Defendants
Axchem distributes specialty chemicals (AXSTRENGTH®), while SNF is a multinational polyacrylamide producer with competing GPAM products.
Patents at Issue
This case involved three U.S. patents covering Glyoxalated Polyacrylamide (GPAM) polymer technology, crucial for paper strength additives:
- • US7,875,676 B2 — Relates to the synthesis of GPAM polymers
- • US8,222,343 B2 — Covers GPAM polymer compositions and methods of use
- • US8,703,847 B2 — Pertains to specific applications of GPAM as paper strength additives
Developing similar chemical formulations?
Check if your specialty polymer technology might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
Judge Eleanor L. Ross **dismissed** Solenis’ complaint **without prejudice** under Federal Rule of Civil Procedure 12(b)(6) for failure to state a claim. No merits determination was made regarding the underlying GPAM patents.
Key Legal Issues
The dismissal stemmed from fundamental pleading deficiencies, emphasizing that patent infringement complaints must include sufficient factual allegations to plausibly establish infringement, going beyond mere product identification. The court found Solenis’ complaint lacked the necessary claim-level factual mapping.
Filing a chemical patent?
Learn from this procedural case. Use AI to draft stronger complaints with rigorous factual allegations.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in specialty polymer chemistry. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in GPAM technology.
- View all related patents in this technology space
- See which companies are most active in GPAM patents
- Understand claim construction patterns for polymers
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own GPAM or related chemical product.
- Input your product description or technical features
- AI identifies potentially blocking patents (e.g., Solenis’ GPAM portfolio)
- Get actionable risk assessment report
Active Enforcement
Solenis has an aggressive IP enforcement strategy
3 Key Patents
US7,875,676; US8,222,343; US8,703,847 B2
Pleading Stage Failure
No merits determination on GPAM patents
✅ Key Takeaways
For Patent Attorneys & Litigators
Rule 12(b)(6) is a viable early-exit strategy; invest in rigorous pre-answer motion practice.
Search related case law →Complaints must plausibly plead claim-level infringement; product identification alone is insufficient post-*Twombly/Iqbal*.
Explore precedents →For R&D Teams & IP Professionals
Conduct thorough FTO analysis against Solenis’ GPAM patents (US7,875,676; US8,222,343; US8,703,847) before entering the paper strength additives market.
Start FTO analysis for my product →Be aware of active IP enforcement in specialty chemical markets; a multi-patent portfolio often signals litigation appetite.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.